Drug Profile
KCP 506
Alternative Names: alpha9/alpha10 nicotinic acetylcholine receptor antagonist - Kineta; KCP-506; nAChR antagonist - KinetaLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Kineta
- Class Non-opioid analgesics
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Netherlands
- 11 Apr 2023 Kineta completes a phase I trial in Neuropathic pain (In volunteers) in Netherlands
- 10 Aug 2021 Kineta has patent protection for KCP 506, covering composition of matter patent, modifications and uses of conotoxin peptides in USA